AOTMiT: Transparency Council on Alagille syndrome and colorectal cancer, among others

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Kayfanda (odevixibatum) under drug program B.175. "Treatment of patients with Alagille syndrome (ICD-10 Q44.7)".
2. Preparation of a position paper on the evaluation of the drugs Opdivo (nivolumabum) and Yervoy (ipilimumabum) under the drug program: B.4. "Treatment of patients with colorectal cancer (ICD-10: C18-C20).
3. Preparation of an opinion on recommended medical technologies, activities carried out within the framework of health policy programs and the conditions for implementation of these programs in the field of prevention and early detection of head and neck cancer.

Source: AOTMiT